Imperial College London

Professor Matthew J. Fuchter

Faculty of Natural SciencesDepartment of Chemistry

Professor of Chemistry



+44 (0)20 7594 5815m.fuchter




110DMolecular Sciences Research HubWhite City Campus





Matthew Fuchter is a Professor of Chemistry, co-Director of the Centre for Drug Discovery Science and co-Director of the MRes in Drug Discovery in the Department of Chemistry, Imperial College London. He is also a Founder, NED and the chemistry lead for NK:IO Ltd. Beyond this, he is the UK representative to the EuCheMS Division of Organic Chemistry, a Theme Champion for the Emerging Technologies Theme of the Centre for Processable Electronics, and an Editorial Board Member for the journals RSC Medicinal Chemistry (formally MedChemComm) and Chirality. He was formally a member of the Organic Division Council of the Royal Society of Chemistry, and an Associate Editor of RSC Medicinal Chemistry. He is involved in multiple multidisciplinary centres of excellence at Imperial including the Institute of Chemical Biology, the Imperial College Network of Excellence in Malaria, the Cancer Research Centre of Excellence, the Antimicrobial Research Collaborative, the Centre for Processable Electronics and the London Centre for Nanotechnology.

See his research group website.


Professor Matthew Fuchter obtained his first class honours degree (MSci in Chemistry) from the University of Bristol in 2002, where he was awarded the Richard N. Dixon prize as well as an undergraduate Scholarship and several faculty commendations.

In January 2006 he completed his PhD research entitled “Synthetic Studies on Porphyrazines: Biological Applications and New Preparative Methods” under the supervision of Professor Anthony G. M. Barrett, FRS FMedSci  (Imperial College London, UK) and in close collaboration with Professor Brian Hoffman (Northwestern University, USA). Following a short spell as a Research Associate at Imperial College, Professor Fuchter was appointed as a CSIRO Research Fellow at the Commonwealth Scientific and Industrial Research Organisation, Australia as well as a Visiting Fellow at the University of Melbourne, where he worked with Professor Andrew B Holmes, FRS.

He briefly took up an independent Fellowship position in 2007 at the School of Pharmacy (University of London), before being appointed as a Lecturer in Synthetic and Medicinal Chemistry at Imperial College London in July 2008. He was subsequently promoted to Senior Lecturer in July 2012, Reader in September 2015 and Professor in September 2018.

Professor Fuchter has been awarded a number of prizes in recognition of his work. These include the RSC Harrison-Meldola Memorial Prize (2014), 2nd prize for a Young Medicinal Chemist in Academia (2015), conferred by the European Federation for Medicinal Chemistry (EFMC), a 2017 Imperial College President’s Excellence in Research Award and a President’s Medal (together with Professors Tony Barrett, Charles Coombes and Simak Ali) for Excellence in Innovation and Entrepreneurship, the 2018 Tetrahedron Young Investigator Award for Bioorganic and Medicinal Chemistry, a Blavatnik Award for Young Scientists in the United Kingdom (2020), conferred by the Blavatnik Family Foundation and the New York Academy of Sciences, and the RSC Corday-Morgan Prize (2021).



Wan L, Wade J, Wang X, et al., 2022, Engineering the sign of circularly polarized emission in achiral polymer – chiral small molecule blends as a function of blend ratio, Journal of Materials Chemistry C, Vol:10, ISSN:2050-7526, Pages:5168-5172

Liu T, Shi W, Tang W, et al., 2022, High responsivity circular polarized light detectors based on quasi two-dimensional chiral perovskite films., Acs Nano, Vol:16, ISSN:1936-0851, Pages:2682-2689

McNeish I, Spiliopoulou P, Spear S, et al., 2022, Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high-grade serous carcinoma, Molecular Cancer Therapeutics, Vol:21, ISSN:1535-7163, Pages:522-534

dos Santos JM, Sun D, Moreno-Naranjo JM, et al., 2022, An S-shaped double helicene showing both multi-resonance thermally activated delayed fluorescence and circularly polarized luminescence, Journal of Materials Chemistry C, Vol:10, ISSN:2050-7526, Pages:4861-4870


Howell SJ, Kenny LM, Lord S, et al., 2022, A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC), San Antonio Breast Cancer Symposium, AMER ASSOC CANCER RESEARCH, ISSN:0008-5472

More Publications